In Focus channel feed
Can AI do scientific research? Billions are pouring in to find out
3 weeks ago
Fetal gene therapy inches closer. Will embryo editing follow?
4 weeks ago
Bristol Myers reaches a crossroads as a make-or-break year takes shape
Last month
Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
Last month
Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete?
Last month
How pharma is capitalizing on the sudden revival and success of an old asthma drug
2 months ago
A simpler, single-strand form of DNA may be key to non-viral gene therapy, study suggests
3 months ago
How GLP-1 weight loss compounders reshaped the drug industry
3 months ago
After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there
3 months ago
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans
3 months ago
Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
3 months ago
Exclusive: First test of gene therapy for rare form of autism is underway
3 months ago
More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem
4 months ago
Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters
4 months ago
Gene editing's search for a 'holy grail' has led to an explosion of tools, but few cures
5 months ago
The Endpoints winners and losers list: Who was up and who was down in 2025
5 months ago
Models are out, molecules are in as AI startups sprint to clinic
6 months ago
China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in
6 months ago
As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myers
6 months ago
Are recent strides in neurology R&D enough to make it a hot M&A target?
7 months ago
Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?
8 months ago
In China, a low-cost push to rival a life-saving, $2M medicine
8 months ago
David Reese bets his career on the 'hinge moment' for AI at Amgen
8 months ago
Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss
9 months ago